Acumen Pharmaceuticals, Inc. · NASDAQ:ABOS

Acumen Pharmaceuticals — FY 2021 Earnings Presentation

11 slides from Acumen Pharmaceuticals's earnings presentation, Mar 28, 2022

  1. Slide 1: FY 2021 Financial Results & Business Highlights

    FY 2021 Financial Results & Business Highlights March 28, 2022 1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and

  3. Slide 3: Advancing a Potential Best-/First-In-Class Antibody for Early Alzheimer's disease

    Advancing a Potential Best-/First-In-Class Antibody for Early Alzheimer’s disease (Early AD) $ Alzheimer’s Scientific ACU193: First, Experienced Strong Balance Phase 1 Clinical Represents an Consensus Clinical-Stage Leadership Sheet: Trial in Early AD Enormous Supports Monoclonal Comprised of 2021 S

  4. Slide 4: Strong Momentum Heading into 2022

    Strong Momentum Heading into 2022 • 2021: Transformational year for Acumen ✓ Series B Tranche gross proceeds of $30M and IPO with gross proceeds of $184M ✓ INTERCEPT-AD trial launched; first patient dosed in October ✓ Trial design and program presented at CTAD in November ✓ December 31, 2021: Cash,

  5. Slide 5: INTERCEPT-AD Trial Update

    INTERCEPT-AD Trial Update • INTERCEPT-AD: Phase 1 clinical trial of ACU193 in patients with early AD (RCT) → Topline results under full database lock expected in 1H 2023 ▪ Safety / ARIA-E ▪ PK ▪ Target engagement → Trial timeline also adjusted for COVID-related impact → Trial enrollment on-going at

  6. Slide 6: ACU193's High Selectivity for toxic AβOs, Combined with Expected Lack of ARIA-related Safety Concerns

    ACU193’s High Selectivity for toxic AβOs, Combined with its Expected Lack of ARIA-related Safety Concerns, Is Anticipated to Provide Superior Efficacy Compared to Peers TARGET SELECTIVITY+ SAFETY PROFILE Company Asset Amyloid plaque Aβ fibrils Aβ monomers Aβ oligomers Lack of ARIA ACU193  untested

  7. Slide 7: INTERCEPT-AD trial: Phase 1 Overview

    (ACU-001) INTERCEPT-AD trial: Phase 1 Overview TRIAL Randomized Placebo Controlled Phase 1 DESIGN: • Part A : Single-Ascending Doses • Part B : Multiple-Ascending Doses ENROLLMENT Early AD CRITERIA: • Mild Cognitive Impairment and Mild Dementia due to AD (amyloid positive by PET) TRIAL Proof of Mech

  8. Slide 8: INTERCEPT-AD a Randomized Placebo Controlled Phase 1 in Early AD patients

    INTERCEPT-AD a Randomized Placebo Controlled Phase 1 in Early AD patients COHORT 4: 60mg PART A: ≥ 1wk 60 mg/kg ACU193 SINGLE- or Placebo ASCENDING DOSE COHORT 3: n = 8 per cohort (32 total) ≥ 1wk 25 mg/kg ACU193 25mg or Placebo COHORT 2: ≥ 1wk 10 mg/kg ACU193 10mg or Placebo ≥ 1wk COHORT 1: 2 mg/kg

  9. Slide 9: Phase 1 Objectives: Proof of Mechanism

    Phase 1 Objectives: Proof of Mechanism 1. SAFETY AND TOLERABILITY • Assessment of ARIA-E • Absence of problematic immunogenicity PROOF OF MECHANISM 2. PHARMACOKINETICS Requirements for Phase 2/3 • Peripheral and Central ✓ Acceptable safety and 3. EVIDENCE OF TARGET ENGAGEMENT tolerability • CSF leve

  10. Slide 10: Acumen is Well Capitalized, with Expected Cash Runway through 2025

    Acumen is Well Capitalized, with Expected Cash Runway through 2025 to Achieve Multiple Anticipated Clinical Milestones MILESTONES STATUS/EXPECTED TIMING ✓ Initiated Ph1 clinical trial INTERCEPT-AD ~$225M INTERCEPT-AD trial updates 2022 Cash and marketable securities as of December 31, 2021 Proof of

  11. Slide 11: Thank you - Q&A

    Thank you - Q&A Ace ae

Acumen Pharmaceuticals — FY 2021 Earnings Presentation on 6ix